I believe the market is already valuing NNZ-2591.
The SP rise from the readout of phase 11 success in Phelan McDermid late last year added approximately $1b to Neuren’s market cap. Assuming there was also some value for the market in the molecule prior to that result then the market appears to be valuing each of Trofinetide and NNZ-2591 equally at this time.
I suspect in a few months time NNZ-2591 value in the market will be significantly more.
I believe the market is already valuing NNZ-2591.The SP rise...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.70 |
Change
0.520(2.71%) |
Mkt cap ! $2.515B | |||
| Open | High | Low | Value | Volume |
| $19.39 | $19.84 | $19.28 | $5.675M | 288.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1531 | $19.66 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.81 | 557 | 1 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.70 |
Change
0.520 ( 2.59 %) |
||||
| Open | High | Low | Volume | ||
| $19.50 | $19.84 | $19.28 | 87628 | ||
| Last updated 15.59pm 03/05/2024 ? | |||||
| NEU (ASX) Chart |